EBR Systems shares jump after confirmation of first commercial US implants
Make us a preferred source
Make us a preferred source on Google
The news: Shares in EBR Systems surged at market open after the medical devices company's WiSE cardiac resynchronisation therapy (CRT) system was implanted in the first commercial patients in the US.
The numbers: EBR shares were up 7.2% to $1.19 at 10:40am AEST.
The context: The procedures took place at two US institutions that are participating in a pilot release of the WiSE CRT system — a wireless cardiac pacing device for heart failure — following recent approval by the US Food and Drug Administration.
EBR said it remains on track for the system's limited market release and expects reimbursement add-on payments to commence in October.
The source: ASX
